Cysteamine/Cystamine Exert Anti-Mycobacterium abscessus Activity Alone or in Combination with Amikacin

Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants

(2022) Tonino Alonzi et al.   Cell Death Discovery

Host‐directed therapy to combat mycobacterial infections*

(2021) Gül Kilinç et al.   IMMUNOLOGICAL REVIEWS

Beyond phenotype: The genomic heterogeneity of co-infecting Mycobacterium abscessus smooth and rough colony variants in cystic fibrosis patients

(2021) Ana Victoria Gutiérrez et al.   Journal of Cystic Fibrosis

Transglutaminase 2 Regulates Innate Immunity by Modulating the STING/TBK1/IRF3 Axis

(2021) Luca Occhigrossi et al.   JOURNAL OF IMMUNOLOGY

The role of amikacin in the treatment of nontuberculous mycobacterial disease

(2021) Jelmer Raaijmakers et al.   EXPERT OPINION ON PHARMACOTHERAPY

Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy

(2021) Tonino Alonzi et al.   Cells

Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus

(2020) Matt D. Johansen et al.   NATURE REVIEWS MICROBIOLOGY

Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against Mycobacterium tuberculosis

(2020) Ivana Palucci et al.   Frontiers in Immunology

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

(2020) Safiya Richardson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Formulation of host-targeted therapeutics against bacterial infections

(2020) Devika M. Varma et al.   Translational Research

Host Directed Therapy Against Infection by Boosting Innate Immunity

(2020) Peter Bergman et al.   Frontiers in Immunology

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

(2020) Charles L Daley et al.   CLINICAL INFECTIOUS DISEASES

Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial

(2020) Graham Devereux et al.   PLoS One

Type I interferon induced by TLR2-TLR4-MyD88-TRIF-IRF3 controls Mycobacterium abscessus subsp. abscessus persistence in murine macrophages via nitric oxide

(2019) Nanthapon Ruangkiattikul et al.   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY

How mycobacteria take advantage of the weakness in human immune system in the modern world

(2019) Wen-Cheng Chao et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease

(2018) Ivana Palucci et al.   CHEMOTHERAPY

NTM drug discovery: status, gaps and the way forward

(2018) Mu-Lu Wu et al.   DRUG DISCOVERY TODAY

Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo

(2018) Thomas M. Jeitner et al.   BIOSCIENCE REPORTS

Cysteamine revisited: repair of arginine to cysteine mutations

(2017) L. Gallego-Villar et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection

(2017) I. Palucci et al.   JOURNAL OF INTERNAL MEDICINE

Enhanced respiration prevents drug tolerance and drug resistance inMycobacterium tuberculosis

(2017) Catherine Vilchèze et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation

(2017) Eleonora Ferrari et al.   Cell Death & Disease

Mycobacterial infection induces higher interleukin-1β and dysregulated lung inflammation in mice with defective leukocyte NADPH oxidase

(2017) Wen-Cheng Chao et al.   PLoS One

Mycobacterial Characteristics and Treatment Outcomes inMycobacterium abscessusLung Disease

(2016) Won-Jung Koh et al.   CLINICAL INFECTIOUS DISEASES

Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases

(2016) Jakko van Ingen et al.   EUROPEAN RESPIRATORY JOURNAL

Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

(2016) Robert S Wallis et al.   LANCET INFECTIOUS DISEASES

The distinct fate of smooth and roughMycobacterium abscessusvariants inside macrophages

(2016) Anne-Laure Roux et al.   Open Biology

Mycobacterium abscessus-Induced Granuloma Formation Is Strictly Dependent on TNF Signaling and Neutrophil Trafficking

(2016) Audrey Bernut et al.   PLoS Pathogens

Mycobacteria Clumping Increase Their Capacity to Damage Macrophages

(2016) Cecilia Brambilla et al.   Frontiers in Microbiology

Characterization of Host and Microbial Determinants in Individuals with Latent Tuberculosis Infection Using a Human Granuloma Model

(2015) Evelyn Guirado et al.   mBio

Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum

(2015) Graham Devereux et al.   EBioMedicine

Microbiological Features and Clinical Relevance of New Species of the Genus Mycobacterium

(2014) Enrico Tortoli   CLINICAL MICROBIOLOGY REVIEWS

Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections

(2014) R. J. Wallace et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk

(2014) Katrin D. Mayer-Barber et al.   NATURE

Targeting the Inflammatory Response in Tuberculosis

(2014) Jon S. Friedland   NEW ENGLAND JOURNAL OF MEDICINE

Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis

(2014) Cedric Charrier et al.   Orphanet Journal of Rare Diseases

Mycobacterium abscessus cording prevents phagocytosis and promotes abscess formation

(2014) A. Bernut et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistentMycobacterium abscessus

(2013) Alexandre Pawlik et al.   MOLECULAR MICROBIOLOGY

Modeling the Mycobacterium tuberculosis Granuloma – the Critical Battlefield in Host Immunity and Disease

(2013) Evelyn Guirado et al.   Frontiers in Immunology

Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections

(2012) David M. Tobin et al.   CELL

Type 2 transglutaminase is involved in the autophagy-dependent clearance of ubiquitinated proteins

(2012) M D'Eletto et al.   CELL DEATH AND DIFFERENTIATION

Mycobacterium abscessus: a new antibiotic nightmare

(2012) R. Nessar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Is Real-Time PCR Better than Conventional PCR for Mycobacterium tuberculosis Complex Detection in Clinical Samples?

(2012) E. Tortoli et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent mycobacterial variants

(2010) Anne-Laure Roux et al.   CELLULAR MICROBIOLOGY

Surface Expression of MPT64 as a Fusion with the PE Domain of PE_PGRS33 Enhances Mycobacterium bovis BCG Protective Activity against Mycobacterium tuberculosis in Mice

(2010) M. Sali et al.   INFECTION AND IMMUNITY

Mycobacterium abscessus Glycopeptidolipids Mask Underlying Cell Wall Phosphatidyl-myo-Inositol Mannosides Blocking Induction of Human Macrophage TNF-  by Preventing Interaction with TLR2

(2009) E. R. Rhoades et al.   JOURNAL OF IMMUNOLOGY